Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1

Biomedicine and Pharmacotherapy

Volumn 66, Issue 8, 2012, Pages 597-602

  Zhao, Xin Yu ^a   Nie, Chun Lai ^a   Liang, Shu Fang ^a   Yuan, Zhu ^a   Deng, Hong Xin ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gemcitabine; Polo like kinase; RNA interference

Indexed keywords

GEMCITABINE; POLO LIKE KINASE 1; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, NUDE; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869868151     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.01.003     Document Type: Article

References (40)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Agrawal N., Dasaradhi P.V., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 2003, 67:657-685.
3. Milhavet O., Gary D.S., Mattson M.P. RNA interference in biology and medicine. Pharmacol Rev 2003, 55:629-648.
4. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev 2004, 5:429-440.
5. Donaldson M.M., Tavares A.A., Hagan I.M., Nigg E.A., Glover D.M. The mitotic roles of Polo-like kinase. J Cell Sci 2001, 114:2357-2358.
6. Sumara I., Gimenez-Abian J.F., Gerlich D., Hirota T., Kraft C., de la Torre C., Ellenberg J., Peters J.M. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004, 14:1712-1722.
7. Dietzmann K., Kirches E., von B., Jachau K., Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neuro Oncol 2001, 53:1-11.
8. Ito Y., Miyoshi E., Sasaki N., Kakudo K., Yoshida H., Tomoda C., Uruno T., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Matsuura N., Kuma K., Miyauchi A. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004, 90:414-418.
9. Kneisel L., Strebhardt K., Bernd A., Wolter M., Binder A., Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002, 29:354-358.
10. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
11. Weichert W., Kristiansen G., Winzer K.J., Schmidt M., Gekeler V., Noske A., Muller B.M., Niesporek S., Dietel M., Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005, 446:442-450.
12. Weichert W., Ullrich A., Schmidt M., Gekeler V., Noske A., Niesporek S., Buckendahl A.C., Dietel M., Denkert C. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 2006, 97:271-276.
13. Weichert W., Denkert C., Schmidt M., Gekeler V., Wolf G., Kobel M., Dietel M., Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004, 90:815-821.
14. Weichert W., Kristiansen G., Schmidt M., Gekeler V., Noske A., Niesporek S., Dietel M., Denkert C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005, 11:5644-5650.
15. Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., Loening S., Dietel M., Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60:240-245.
16. Weichert W., Schmidt M., Jacob J., Gekeler V., Langrehr J., Neuhaus P., Bahra M., Denkert C., Dietel M., Kristiansen G. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005, 5:259-265.
17. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:2794-2797.
18. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., Altmannsberger H.M., Rubsamen-Waigmann H., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549.
19. Wolf G., Hildenbrand R., Schwar C., Grobholz R., Kaufmann M., Stutte H.J., Strebhardt K., Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000, 196:753-759.
20. Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y., Sugano S., Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y., Ando H., Suita S., Kaneko M., Sasaki F., Hashizume K., Ohnuma N., Nakagawara A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004, 23:5901-5911.
21. Elez R., Piiper A., Giannini C.D., Brendel M., Zeuzem S. Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000, 269:352-356.
22. Spankuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96:862-872.
23. Spankuch B., Heim S., Kurunci-Csacsko E., Lindenau C., Yuan J., Kaufmann M., Strebhardt K. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006, 66:5836-5846.
24. Hou S., Zhao Z., Yan F., Chen X., Deng H., Chen X., Wang Y., Wei Y. Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer. Cell Biol Intern 2009, 33:276-282.
25. Wouters A., Pauwels B., Lardon F., Pattyn G.G., Lambrechts H.A., Baay M., Meijnders P., Vermorken J.B. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 2010, 10:441.
26. Liu Q., Zhao X.Y., Bai R.Z., Liang S.F., Nie C.L., Yuan Z., Wang C.T., Wu Y., Chen L.J., Wei Y.Q. Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1. Oncol Rep 2009, 22:1069-10675.
27. Peng X.C., Yang L., Yang L.P., Mao Y.Q., Yang H.S., Liu J.Y., Zhang D.M., Chen L.J., Wei Y.Q. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34->Ala mutant. J Exp Clin Cancer Res 2008, 27:46.
28. Fields M.T., Eisbruch A., Normolle D., Orfali A., Davis M.A., Pu A.T., Lawrence T.S. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine). Intern J Radiat Oncol Biol Phys 2000, 47:785-791.
29. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006, 26:2093-2108.
30. Nogawa M., Yuasa T., Kimura S., Tanaka M., Kuroda J., Sato K., Yokota A., Segawa H., Toda Y., Kageyama S., Yoshiki T., Okada Y., Maekawa T. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005, 115:978-985.
31. Anger M., Kues W.A., Klima J., Mielenz M., Kubelka M., Motlik J., Esner M., Dvorak P., Carnwath J.W., Niemann H. Cell cycle dependent expression of Plk1 in synchronized porcine fetal fibroblasts. Mol Reprod Develop 2003, 65:245-253.
32. Eckerdt F., Yuan J., Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005, 24:267-276.
33. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003, 100:5789-5794.
34. Reagan-Shaw S., Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005, 19:611-613.
35. Duxbury M.S., Ito H., Benoit E., Zinner M.J., Ashley S.W., Whang E.E. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003, 311:786-792.
36. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004, 23:1539-1548.
37. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004, 198:953-959.
38. Ando K., Ozaki T., Yamamoto H., Furuya K., Hosoda M., Hayashi S., Fukuzawa M., Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004, 279:25549-25561.
39. Heinemann V., Schulz L., Issels R.D., Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Sem Oncol 1995, 22:11-18.
40. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anti Cancer drugs 1995, 6(Suppl. 6):7-13.